Jul 29 2014 Boston Therapeutics Appoints Zbigniew J. Witczak, Ph.D., to Its Scientific Advisory Board Read More • 6:30 am EDT
Jul 09 2014 Boston Therapeutics Appoints Benjamin Rivnay, Ph.D. to Chief Scientist Read More • 7:00 am EDT
May 29 2014 Boston Therapeutics Initiates Phase IIb Study to Assess the Efficacy and Safety of SUGARDOWN(R) for Type 2 Diabetes Read More • 7:00 am EDT
May 27 2014 Boston Therapeutics to Present at SeeThruEquity Microcap Investor Conference on May 28 and Marcum Microcap Conference on May 29 Read More • 8:01 am EDT
May 20 2014 Boston Therapeutics Announces Strategic Marketing Agreement With Benchworks SD Aimed at Growing Sales of SUGARDOWN(R) Read More • 7:00 am EDT
May 13 2014 Boston Therapeutics Reports Corporate Update and Financial Results for the First Quarter Ended March 31, 2014 Read More • 12:22 pm EDT
May 06 2014 Boston Therapeutics Signs Agreement With Patheon to Manufacture Pharmaceutical-Grade BTI-320 Tablets Read More • 7:00 am EDT
Apr 29 2014 Boston Therapeutics to Present Late-Breaking Poster on Mechanism of Action for BTI-320 at AACE Annual Congress in Las Vegas on May 14-18 Read More • 6:15 am EDT
Mar 17 2014 Boston Therapeutics Reports Corporate Update and Financial Results for the Fourth Quarter and Year Ended December 31, 2013 Read More • 7:00 am EDT
Mar 04 2014 Boston Therapeutics to Initiate a Phase II Clinical Study of BTI-320 in U.S. Read More • 7:18 am EST
